Fosun Pharma Receives NMPA Clearance to Begin Phase I Trial of siRNA Candidate FXR0906 for Hypertriglyceridemia

Bulletin Express07-15

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Company Limited, has secured approval from China’s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of FXR0906 for the treatment of hypertriglyceridemia.

FXR0906 is a liver-targeted small interfering RNA (siRNA) therapy licensed to Fosun Pharma with exclusive rights for research, development, registration, manufacturing and commercialization in mainland China, Hong Kong and Macau. The drug aims to lower serum triglyceride levels by suppressing APOC3 mRNA expression.

As of June 2026, cumulative research and development investment in FXR0906 totaled approximately RMB 71.00 million, including licence fees (unaudited). To date, no siRNA therapy for hypertriglyceridemia has been approved in China, positioning FXR0906 as a potential first-in-class entrant if future trials prove successful.

The company plans to commence the Phase I study on the Chinese mainland once preparatory conditions are met. Management stresses that drug development entails inherent uncertainties, noting that clinical trials may face termination due to safety or efficacy issues and that market launch is contingent upon the completion of all regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171193415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171193415","market":"us","top_or_hot":-1,"title":"Fosun Pharma Receives NMPA Clearance to Begin Phase I Trial of siRNA Candidate FXR0906 for Hypertriglyceridemia","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Company Limited, has secured approval from China’s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of FXR0906 for the treatment of hypertriglyceridemia.</p>\n<p>FXR0906 is a liver-targeted small interfering RNA (siRNA) therapy licensed to Fosun Pharma with exclusive rights for research, development, registration, manufacturing and commercialization in mainland China, Hong Kong and Macau. The drug aims to lower serum triglyceride levels by suppressing APOC3 mRNA expression.</p>\n<p>As of June 2026, cumulative research and development investment in FXR0906 totaled approximately RMB 71.00 million, including licence fees (unaudited). To date, no siRNA therapy for hypertriglyceridemia has been approved in China, positioning FXR0906 as a potential first-in-class entrant if future trials prove successful.</p>\n<p>The company plans to commence the Phase I study on the Chinese mainland once preparatory conditions are met. Management stresses that drug development entails inherent uncertainties, noting that clinical trials may face termination due to safety or efficacy issues and that market launch is contingent upon the completion of all regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Receives NMPA Clearance to Begin Phase I Trial of siRNA Candidate FXR0906 for Hypertriglyceridemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Receives NMPA Clearance to Begin Phase I Trial of siRNA Candidate FXR0906 for Hypertriglyceridemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-15 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Company Limited, has secured approval from China’s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of FXR0906 for the treatment of hypertriglyceridemia.</p>\n<p>FXR0906 is a liver-targeted small interfering RNA (siRNA) therapy licensed to Fosun Pharma with exclusive rights for research, development, registration, manufacturing and commercialization in mainland China, Hong Kong and Macau. The drug aims to lower serum triglyceride levels by suppressing APOC3 mRNA expression.</p>\n<p>As of June 2026, cumulative research and development investment in FXR0906 totaled approximately RMB 71.00 million, including licence fees (unaudited). To date, no siRNA therapy for hypertriglyceridemia has been approved in China, positioning FXR0906 as a potential first-in-class entrant if future trials prove successful.</p>\n<p>The company plans to commence the Phase I study on the Chinese mainland once preparatory conditions are met. Management stresses that drug development entails inherent uncertainties, noting that clinical trials may face termination due to safety or efficacy issues and that market launch is contingent upon the completion of all regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1171193415","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171193415","pubTimestamp":1784110999,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Company Limited, has secured approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药获得NMPA批准，开始siRNA候选药物FXR0906治疗高甘油三酯血症的I期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Company Limited, has secured approval from China’s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of FXR0906 for the treatment of hypertriglyceridemia.\nFXR0906 is a liver-targeted small interfering RNA (siRNA) therapy licensed to Fosun Pharma with exclusive rights for research, development, registration, manufacturing and commercialization in mainland China, Hong Kong and Macau. The drug aims to lower serum triglyceride levels by suppressing APOC3 mRNA expression.\nAs of June 2026, cumulative research and development investment in FXR0906 totaled approximately RMB 71.00 million, including licence fees (unaudited). To date, no siRNA therapy for hypertriglyceridemia has been approved in China, positioning FXR0906 as a potential first-in-class entrant if future trials prove successful.\nThe company plans to commence the Phase I study on the Chinese mainland once preparatory conditions are met. Management stresses that drug development entails inherent uncertainties, noting that clinical trials may face termination due to safety or efficacy issues and that market launch is contingent upon the completion of all regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171193415","isCrawlerRequest":true}